Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN92984394
ISRCTN92984394
Completed
N/A

A pilot study to assess flutamide monotherapy compared With maximal androgen blockade in metastatic prostate cancer

Schering-Plough Ltd (UK)0 sites0 target enrollmentAugust 19, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancerCancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Schering-Plough Ltd (UK)
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 19, 2002
End Date
September 30, 1996
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Schering-Plough Ltd (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Histologically confirmed prostate carcinoma
  • •2\. Skeletal metastases on bone scan, with radiological conformation if appropriate, or typical sclerotic metastases on X\-ray
  • •3\. Life expectancy \>6 months
  • •4\. Suitable for treatment by any of the study therapies
  • •5\. No previous hormonal therapy
  • •6\. Not currently receiving corticosteroids, spironolactone or aminoglutethamide
  • •7\. Adequate renal and hepatic function

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
Clinical study on the efficacy of flutamide for androgen dependent dilated cardiomyopathy
JPRN-jRCTs051180123Onoue Kenji2
Completed
Phase 3
Clinical trial on the effectiveness of the Famotidine on symptoms of schizophrenic patients
IRCT20190707044123N1Rasht University of Medical Sciences64
Recruiting
Phase 2
eflunomide for musculoskeletal GVHD after allogeneic stem cell transplant
CTRI/2021/04/033214Dr Sachin Punatar
Recruiting
N/A
A pilot study to evaluate the efficacy of lafutidine in patients with paclitaxel-induced peripheral neuropathy.gynecological cancer
JPRN-UMIN000011890Fukushima medical University Hospital, School of medicine30
Active, Not Recruiting
N/A
Multicentric Pilot Phase II Study for use of Fludarabine plus Cyclophosphamide Followed by 90 Y-Ibritumomab Tiuxetan Zevalin in the Treatment of non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing FludarabineTreatment patients with non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine and Ciclofosfamide
EUCTR2005-000699-41-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE80